open access

Vol 25, No 3 (2019)
Original papers
Published online: 2019-09-30
Get Citation

The novel minimally invasive mechano-chemical technique of the saphenous vein ablation. Our center experience: results of 24 months follow-up

Marek Iłżecki, Piotr Terlecki, Stanisław Przywara, Joanna Iłżecka, Tomasz Zubilewicz
DOI: 10.5603/AA.2019.0008
·
Acta Angiologica 2019;25(3):127-132.

open access

Vol 25, No 3 (2019)
Original papers
Published online: 2019-09-30

Abstract

Introduction: The aim of the study was to evaluate the efficacy of the endovascular ablation method of GSV/
/SSV superficial venous insufficiency using Flebogrif® catheter, the safety of the method, expressed in number
and quality of observed complications in 24-month observation.

Material and methods: Initially, the observed group included 200 patients undergoing ablation of insufficient
GSV/SSV. During 24 months of observation, this number decreased to 158, which seems to be a natural process.
All patients signed the informed consent form approved by the Bioethics Committee of the Medical University
of Lublin. Based on clinical evaluation, including ultrasound assessment, 200 patients, including 170 women
and 30 men, were admitted to the study using the adopted criteria of inclusion/exclusion. In the studied group
of patients, 172 great saphenous veins (GSV) and 28 short saphenous veins (SSV) were ablated. The treated
inefficient veins were punctured at three levels depending on the length of the segment of insufficient GSV/SSV.
Each patient was treated with a compression agent in the form of a second compression class elastic stockings
(20–30 mm Hg). Control visits on the basis of the accepted protocol were established in 1, 3, 6, 12, 24, 36
months after the procedure.

Results: During 24 months of observation, the evaluation of the Flebogrif® catheter method was based on the
analysis of results obtained in four categories: effectiveness of the method, expressed as the ratio of the number
of successfully closed veins ablated with the Flebogrif® catheter to the number of observed cases of recanalization;
clinical improvement of venous insufficiency symptoms, based on the VCSS, CEAP, VAPS scale; safety of
the method, expressed in terms of quantity and quality of observed complications; technical characteristics
of the method. The obtained results were analyzed statistically using tests for non-parametric variables. The
effectiveness of the method based on the obtained results was 92%. A statistically significant decrease in the
intensity of clinical symptoms in relation to the preoperative condition was observed. The number and quality of
the observed complications allow considering the procedure of vein ablation with the use of Flebogrif® catheter
as safe, possible to perform in ambulatory conditions.

Conclusions: Effectiveness of the method of 92% in 24-month observation; good cosmetic effect; a statistically
significant decrease in the intensity of clinical symptoms in 24-month observation; the low incidence of
complications allows to consider the method safe; the method of surgery allows to perform the procedure in
ambulatory conditions.

Abstract

Introduction: The aim of the study was to evaluate the efficacy of the endovascular ablation method of GSV/
/SSV superficial venous insufficiency using Flebogrif® catheter, the safety of the method, expressed in number
and quality of observed complications in 24-month observation.

Material and methods: Initially, the observed group included 200 patients undergoing ablation of insufficient
GSV/SSV. During 24 months of observation, this number decreased to 158, which seems to be a natural process.
All patients signed the informed consent form approved by the Bioethics Committee of the Medical University
of Lublin. Based on clinical evaluation, including ultrasound assessment, 200 patients, including 170 women
and 30 men, were admitted to the study using the adopted criteria of inclusion/exclusion. In the studied group
of patients, 172 great saphenous veins (GSV) and 28 short saphenous veins (SSV) were ablated. The treated
inefficient veins were punctured at three levels depending on the length of the segment of insufficient GSV/SSV.
Each patient was treated with a compression agent in the form of a second compression class elastic stockings
(20–30 mm Hg). Control visits on the basis of the accepted protocol were established in 1, 3, 6, 12, 24, 36
months after the procedure.

Results: During 24 months of observation, the evaluation of the Flebogrif® catheter method was based on the
analysis of results obtained in four categories: effectiveness of the method, expressed as the ratio of the number
of successfully closed veins ablated with the Flebogrif® catheter to the number of observed cases of recanalization;
clinical improvement of venous insufficiency symptoms, based on the VCSS, CEAP, VAPS scale; safety of
the method, expressed in terms of quantity and quality of observed complications; technical characteristics
of the method. The obtained results were analyzed statistically using tests for non-parametric variables. The
effectiveness of the method based on the obtained results was 92%. A statistically significant decrease in the
intensity of clinical symptoms in relation to the preoperative condition was observed. The number and quality of
the observed complications allow considering the procedure of vein ablation with the use of Flebogrif® catheter
as safe, possible to perform in ambulatory conditions.

Conclusions: Effectiveness of the method of 92% in 24-month observation; good cosmetic effect; a statistically
significant decrease in the intensity of clinical symptoms in 24-month observation; the low incidence of
complications allows to consider the method safe; the method of surgery allows to perform the procedure in
ambulatory conditions.

Get Citation

Keywords

mechano-chemical ablation, Flebogrif®, sclerosant, endovascular treatment, ablation, varicose veins, great saphenous vein, short saphenous vein

About this article
Title

The novel minimally invasive mechano-chemical technique of the saphenous vein ablation. Our center experience: results of 24 months follow-up

Journal

Acta Angiologica

Issue

Vol 25, No 3 (2019)

Pages

127-132

Published online

2019-09-30

DOI

10.5603/AA.2019.0008

Bibliographic record

Acta Angiologica 2019;25(3):127-132.

Keywords

mechano-chemical ablation
Flebogrif®
sclerosant
endovascular treatment
ablation
varicose veins
great saphenous vein
short saphenous vein

Authors

Marek Iłżecki
Piotr Terlecki
Stanisław Przywara
Joanna Iłżecka
Tomasz Zubilewicz

References (19)
  1. Evans CJ, Fowkes FG, Ruckley CV, et al. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. J Epidemiol Community Health. 1999; 53: 149–153.
  2. Sudoł-Szopińska I. Błachowiak K. Koziński P. Wpływ czynników środowiskowych na rozwój przewlekłej niewydolności żylnej* influence of environmental risk factors on the development of chronic vein insufficiency. Med Pr. 2006; 57(4): 365–373.
  3. van Eekeren RR, Boersma D, de Vries JPPM, et al. Update of endovenous treatment modalities for insufficient saphenous veins--a review of literature. Semin Vasc Surg. 2014; 27(2): 118–136.
  4. Leopardi D, Hoggan BL, Fitridge RA, et al. Systematic review of treatments for varicose veins. Ann Vasc Surg. 2009; 23(2): 264–276.
  5. Ciostek P, Kowalski M, Woźniak W, et al. Phlebogriffe — a new device for mechanochemical ablation of incompetent saphenous veins: a pilot study. Phlebological Review. 2015; 3: 72–77.
  6. Zubilewicz T, Terlecki P, Przywara S, et al. Applications of mechanochemical ablation with Flebogrif to treat varicose veins of lower extremities: a single center experience over 3 months observation. Acta Angiol. 2006; 22(4): 137–142.
  7. Breu FX, Guggenbichler S, Wollmann J. 2nd European Consensus Meeting on Foam Sclerotherapy 2006, Tegernsee, Germany. Vasa. 2008; 37 (Suppl 71): 1–29.
  8. Jindal R, Verma D, Kaur T, et al. Mechanochemical endovenous ablation: Latest varicose vein treatment. J Vasc Endovasc Surg. 2019(6): 44–46.
  9. van den Bos RR, Milleret R, Neumann M, et al. Proof-of-principle study of steam ablation as novel thermal therapy for saphenous varicose veins. J Vasc Surg. 2011; 53(1): 181–186.
  10. Milleret R, Mehier H, Llopinet A, et al. Oblitération veineuse par vapeur à haute température. Phlebologie. 2008; 61: 223–226.
  11. Milleret R, Huot L, Nicolini P, et al. Great Saphenous Vein Ablation with Steam Injection: Results of a Multicentre Study. European Journal of Vascular and Endovascular Surgery. 2013; 45(4): 391–396.
  12. Dos Santos JB, Júnior WC, Porta RMp, et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: A randomized controlled trial. Phlebology. 2019 [Epub ahead of print]: 268355519850651.
  13. Kurdal AT, Yildirim F, Ozbakkaloglu A, et al. Ultrasound-guided catheter-directed foam sclerotherapy for great saphenous vein. Minerva Chir. 2015; 70(1): 33–36.
  14. Iłżecki M, Terlecki P, Przywara S, et al. A new device for minimally invasive mechano-chemical method of saphenous vein ablation. Report of 12 months of follow up. Acta Angiol. 2018; 24(3): 70–73.
  15. van Eekeren RR, Hillebrands JL, van der Sloot K, et al. Histological observations one year after mechanochemical endovenous ablation of the great saphenous vein. J Endovasc Ther. 2014; 21(3): 429–433.
  16. Whiteley MS, Dos Santos SJ, Lee CT, et al. Mechanochemical ablation causes endothelial and medial damage to the vein wall resulting in deeper penetration of sclerosant compared with sclerotherapy alone in extrafascial great saphenous vein using an ex vivo model. J Vasc Surg Venous Lymphat Disord. 2017; 5(3): 370–377.
  17. Tal MG, Dos Santos SJ, Marano JP, et al. Histologic findings after mechanochemical ablation in a caprine model with use of ClariVein. J Vasc Surg Venous Lymphat Disord. 2015; 3(1): 81–85.
  18. Moore HM, Lane TRA, Franklin IJ, et al. Retrograde mechanochemical ablation of the small saphenous vein for the treatment of a venous ulcer. Vascular. 2014; 22(5): 375–377.
  19. McHugh SM, Leahy AL. What next after thermal ablation for varicose veins: non-thermal ablation? Surgeon. 2014; 12(5): 237–238.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl